Axon Enterprise (NASDAQ:AXON) Stock Keeps "Overweight" Rating at Piper Sandler

Key Points

• Piper Sandler reiterated its “Overweight” rating on Axon but lowered its price target from $561 to $540, implying about 41% upside from the stock’s quoted price.
• Analyst sentiment overall remains positive: 13 analysts rate the stock Buy and four Hold, for a “Moderate Buy” consensus and an average target of $644.56.
• Axon’s latest quarter missed earnings and revenue estimates, despite revenue growing 27.8% year over year. The article also cites a reduced outlook, with federal drone deployment delays weighing on expectations.

Axon Enterprise (NASDAQ:AXON - Get Free Report)'s stock had its "overweight" rating reiterated by investment analysts at Piper Sandler in a report issued on Friday, Benzinga reports. They currently have a $540.00 price objective on the biotechnology company's stock, down from their prior price objective of $561.00. Piper Sandler's target price points to a potential upside of 41.15% from the company's current price.

A number of other analysts have also commented on the company. Barclays raised their price target on Axon Enterprise from $523.00 to $688.00 and gave the stock an "overweight" rating in a research note on Thursday, August 6th. Craig Hallum downgraded shares of Axon Enterprise from a "buy" rating to a "hold" rating and set a $390.00 price objective on the stock. in a research report on Friday. TD Cowen decreased their price objective on shares of Axon Enterprise from $825.00 to $800.00 and set a "buy" rating for the company in a report on Monday, October 26th. Royal Bank Of Canada reaffirmed an "outperform" rating on shares of Axon Enterprise in a research report on Tuesday, July 21st. Finally, Raymond James Financial set a $675.00 target price on shares of Axon Enterprise in a research note on Thursday, October 15th. Thirteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $644.56.

Axon Enterprise Price Performance

AXON opened at $382.56 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.15 and a quick ratio of 1.80. The stock's 50 day simple moving average is $447.49 and its 200 day simple moving average is $476.73. The firm has a market cap of $31.08 billion, a price-to-earnings ratio of 158.74, a PEG ratio of 8.06 and a beta of 1.48. Axon Enterprise has a 1 year low of $339.01 and a 1 year high of $665.07.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings data on Friday, November 6th. The biotechnology company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.89 by ($0.17). The company had revenue of $908.55 million during the quarter, compared to the consensus estimate of $934.33 million. Axon Enterprise had a net margin of 6.19% and a return on equity of 2.84%. The business's revenue for the quarter was up 27.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.17 EPS. As a group, analysts predict that Axon Enterprise will post 2.10 earnings per share for the current year.

Insider Transactions at Axon Enterprise

In other Axon Enterprise news, insider Isaiah Fields sold 1,017 shares of the stock in a transaction on Friday, September 11th. The stock was sold at an average price of $480.45, for a total value of $488,617.65. Following the completion of the transaction, the insider owned 56,264 shares in the company, valued at approximately $27,032,038.80. This represents a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Patrick W. Smith sold 10,000 shares of the firm's stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $508.99, for a total value of $5,089,900.00. Following the transaction, the chief executive officer directly owned 3,118,012 shares of the company's stock, valued at $1,587,036,927.88. This represents a 0.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 37,397 shares of company stock valued at $21,234,034. Company insiders own 4.20% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. MassMutual Private Wealth & Trust FSB increased its holdings in shares of Axon Enterprise by 122,993.6% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 461,601 shares of the biotechnology company's stock worth $195,036,000 after buying an additional 461,226 shares during the last quarter. B. Metzler seel. Sohn & Co. AG purchased a new stake in Axon Enterprise during the second quarter valued at approximately $3,854,000. Arrowstreet Capital Limited Partnership purchased a new stake in Axon Enterprise during the first quarter valued at approximately $15,067,000. Brown Lisle Cummings Inc. lifted its stake in shares of Axon Enterprise by 97,231.4% in the 2nd quarter. Brown Lisle Cummings Inc. now owns 34,066 shares of the biotechnology company's stock valued at $19,098,000 after purchasing an additional 34,031 shares during the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of Axon Enterprise by 40.7% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 15,083 shares of the biotechnology company's stock valued at $6,406,000 after purchasing an additional 4,360 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors.

Trending Headlines about Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Axon reported record Q3 revenue of about $909 million, up 28% year over year, and returned to profitability. Drone-as-First-Responder revenue rose 43%, while AI bookings were up more than 50% year to date and AI annual recurring revenue topped $100 million. Read More.
• Positive Sentiment: Axon is investing an additional $1.2 billion in Skydio, bringing its stake to 37%, and will become Skydio’s exclusive public-safety distributor in the U.S. and Canada. The deal could strengthen Axon’s position in drones and related services, though it also represents a substantial investment. Read More.
• Neutral Sentiment: Needham cut its price target from $750 to $500 but retained a Buy rating. Goldman Sachs and JPMorgan also lowered their targets, to $575 and $610, respectively—signaling reduced expectations while maintaining targets above the quoted share price. Read More.
• Negative Sentiment: Q3 adjusted earnings of $1.72 per share and revenue of $908.55 million both missed analyst estimates. Axon’s 2026 revenue outlook is now $3.6 billion versus a $3.7 billion consensus; Q4 revenue guidance of $990 million–$1.0 billion is also below expectations of about $1.1 billion. Federal drone deployment delays are weighing on the outlook. Read More.
• Negative Sentiment: Axon faces a class-action lawsuit concerning its AI-powered license-plate surveillance network, adding legal and reputational uncertainty. Read More.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and connected products for public safety organizations. The company's portfolio includes TASER conducted-energy weapons, body-worn cameras, in-car cameras, and related hardware designed to support law enforcement, corrections, security, and other emergency-response professionals.

Axon also provides cloud-based software for managing digital evidence, records, workflows, real-time operations, investigations, and communications. Its platform is intended to connect hardware, software, and services across the public-safety ecosystem, helping agencies collect, store, analyze, and share operational information.

The company was founded in 1993 as TASER International by Rick Smith and Tom Smith and adopted the name Axon Enterprise in 2017 as it expanded beyond conducted-energy weapons into a broader technology platform.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.